Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эффективность и переносимость препарата Антистакс® у пациентов с хронической венозной недостаточностью – обзор результатов двойного слепого плацебо-контролируемого мультицентрового исследования
Эффективность и переносимость препарата Антистакс® у пациентов с хронической венозной недостаточностью – обзор результатов двойного слепого плацебо-контролируемого мультицентрового исследования
М.Н.Кудыкин. Эффективность и переносимость препарата Антистакс® у пациентов с хронической венозной недостаточностью – обзор результатов двойного слепого плацебо-контролируемого мультицентрового исследования. Consilium Medicum. Хирургия (Прил.). 2011; 2: 13-17.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обзор подготовил доктор медицинских наук М.Н.Кудыкин
Полный текст
Список литературы
1. Van den Oever R, Hepp B, Debbaut B, Simon I. Socioeconomic impact of chronic venous insufficiency. An underestimated public health problem. Int Angiol 1998; 17: 161–7.
2. Fowkes FG, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency. Angiology 2001; 52 (Suppl. 1): S5–15.
3. Rabe E, Pannier-Fischer F, Bromen K et al. Bonner Venenstudie der Deutschen Gesellschaft für Phlebologie – Epidemiologische Untersuchung zur Frage der Haufigkeit und Auspragung von chronischen Venenkrankheiten in der städtischen und ländlichen Wohnbevolkerung. Phlebologie 2003; 32: 1–14.
4. Bergan JJ, Schmid-Schönbein GW. Coleridge Smith PD et al. Chronic venous disease. The New England Journal of Medicine 2006; 355: 488–98.
5. Frick RW. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside and daflon. Angiology 2000; 51 (3): 197–205.
6. Pittler MH. Complementary therapies for chronic venous insufficiency. Focus on Alternative and Complementary Therapies 2001; 6: 3–5.
7. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. The Cochrane Library 2001; 3.
8. Kalus U, Koscielny J, Grigorov A et al. Clinical improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195. A randomised, doubleblind, placebo-controlled cross-over study. Drugs in R&D 2004; 5: 63–71.
9. Kiesewetter H, Koscielny J, Kalus U et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I–II). A randomized, double-blind, placebo-controlled trial. Arzneimittelforschung 2000; 50: 109–17.
10. Martinez MJ, Bonfill X, Moreno RM et al. Phlebotonics for venous insufficiency, Cochrane Database Syst Rev 2005; 3: CD003229.
11. Rabe E, Stücker M, Ottillinger B. Water displacement leg volumetry in clinical studies – a discussion of error sources. BMC Med Res Methodol 2010; 10 (1): 5.
12. Marshall M, Loew D, Schwahn-Schreiber C. Hydroxyethylrutoside zur Behandlung der chronischen Veneninsuffizienz Grad I und II. Phlebologie 2005; 34: 157–64.
13. Marshall M, Medikamentöse Therapie von chronischen Venenleiden, TW Dermatologie 1993; 23: 244–8.
14. Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, NJ: Erlbaum, 1988.
15. Gallenkemper G, Bulling BJ, Gerlach H et al. Leitlinien zur Diagnostik und Therapie der chronischen venösen Insuffizienz (CVI). Phlebologie 1998; 27: 32–5.
16. Deutsche Gesellschaft für Phlebologie, Diagnostik und Therapie des Ulcus cruris venosum. S3-Leitlinie der Deutschen Gesellschaft für Phlebologie, AWMF Guideline Register 2008; 037 (9).
17. Jünger M, Partsch B, Kahle B et al. Leitlinie: Phlebologischer Kompressionsverband (PKV), AWMF Guideline Register 2009; 037 (5).
18. Belcaro G, Cesarone MR, Ledda A et al. 5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(beta-hydroxyethyl)-rutosides: a prospective comparative clinical registry. Angiology 2008; 59 (Suppl. 1): 14S–20S.
2. Fowkes FG, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency. Angiology 2001; 52 (Suppl. 1): S5–15.
3. Rabe E, Pannier-Fischer F, Bromen K et al. Bonner Venenstudie der Deutschen Gesellschaft für Phlebologie – Epidemiologische Untersuchung zur Frage der Haufigkeit und Auspragung von chronischen Venenkrankheiten in der städtischen und ländlichen Wohnbevolkerung. Phlebologie 2003; 32: 1–14.
4. Bergan JJ, Schmid-Schönbein GW. Coleridge Smith PD et al. Chronic venous disease. The New England Journal of Medicine 2006; 355: 488–98.
5. Frick RW. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside and daflon. Angiology 2000; 51 (3): 197–205.
6. Pittler MH. Complementary therapies for chronic venous insufficiency. Focus on Alternative and Complementary Therapies 2001; 6: 3–5.
7. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. The Cochrane Library 2001; 3.
8. Kalus U, Koscielny J, Grigorov A et al. Clinical improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195. A randomised, doubleblind, placebo-controlled cross-over study. Drugs in R&D 2004; 5: 63–71.
9. Kiesewetter H, Koscielny J, Kalus U et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I–II). A randomized, double-blind, placebo-controlled trial. Arzneimittelforschung 2000; 50: 109–17.
10. Martinez MJ, Bonfill X, Moreno RM et al. Phlebotonics for venous insufficiency, Cochrane Database Syst Rev 2005; 3: CD003229.
11. Rabe E, Stücker M, Ottillinger B. Water displacement leg volumetry in clinical studies – a discussion of error sources. BMC Med Res Methodol 2010; 10 (1): 5.
12. Marshall M, Loew D, Schwahn-Schreiber C. Hydroxyethylrutoside zur Behandlung der chronischen Veneninsuffizienz Grad I und II. Phlebologie 2005; 34: 157–64.
13. Marshall M, Medikamentöse Therapie von chronischen Venenleiden, TW Dermatologie 1993; 23: 244–8.
14. Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, NJ: Erlbaum, 1988.
15. Gallenkemper G, Bulling BJ, Gerlach H et al. Leitlinien zur Diagnostik und Therapie der chronischen venösen Insuffizienz (CVI). Phlebologie 1998; 27: 32–5.
16. Deutsche Gesellschaft für Phlebologie, Diagnostik und Therapie des Ulcus cruris venosum. S3-Leitlinie der Deutschen Gesellschaft für Phlebologie, AWMF Guideline Register 2008; 037 (9).
17. Jünger M, Partsch B, Kahle B et al. Leitlinie: Phlebologischer Kompressionsverband (PKV), AWMF Guideline Register 2009; 037 (5).
18. Belcaro G, Cesarone MR, Ledda A et al. 5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(beta-hydroxyethyl)-rutosides: a prospective comparative clinical registry. Angiology 2008; 59 (Suppl. 1): 14S–20S.
Авторы
М.Н.Кудыкин
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.